// App-Quantinova.ai

PO1012 : Renal Outcomes and All-Cause Death Associated with SGLT-2 Inhibitor vs. Other Glucose-Lowering Drugs (CVD-REAL 3 Korea)

Researchers

Presenter

  • Koh Eun Sil

Principal Investigators

  • Han Kyungdo

  • Lee Hyewon

  • Nam You-Seon

  • Wittbrodt EricT

  • Fenici Peter

  • Kosiborod Mikhail

  • L Heerspink HiddoJan

  • Yoo Soon-Jib

  • Kwon Hyuk-Sang

Medical Centers

  • The Catholic University of Korea Yeouido Saint Mary's Hospital Yeongdeungpo-gu Seoul Korea (the Republic of)

  • Soongsil University, Department of Statistics and Actuarial Science, Rep. of South Korea

  • AstraZeneca Korea Co Ltd Seoul Korea (the Republic of)

  • AstraZeneca Gaithersburg Maryland United States

  • Astra Zeneca, Cambridge, United Kingdom

  • St Lukes Mid America Heart Institute Kansas City Kansas United States

  • University Medical Center Groningen, Nijmegen, Netherlands

  • Catholic University of Korea Bucheon Saint Mary's Hospital Bucheon Gyeonggi-do Korea (the Republic of)

Locations

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Microvascular complications of diabetes 1

  • End stage renal disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved